FDA approves expanded use for Axsome Therapeutics' medication Auvelity. The regulatory decision allows the drug to be prescribed for conditions beyond its current indication for depression.
The FDA has granted Axsome Therapeutics approval for an expanded indication for its medication Auvelity, moving beyond its current use for depression.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near United States
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
Briefings
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.